Fc receptor binding proteins

Patent metadata

Field	Value
Publication number	US-2016304608-A1
Application number	US-201615139784-A
Country	US
Kind code	A1
Filing date	Apr 27, 2016
Priority date	Jun 2, 2011
Publication date	Oct 20, 2016
Grant date	—

Abstract

The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.

First claim

1 - 44 . (canceled)

45 : A kit comprising:
an FcRn-binding antibody comprising a light chain variable region (V L ), a heavy chain variable region (V H ), and a heavy chain constant region (C H ), wherein the V L of the antibody comprises:
(i) a V L CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14);
(ii) a V L CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15); and
(iii) a V L CDR3 comprising the amino acid sequence CSYAGSGIYV (SEQ ID NO: 25), SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID NO: 13);
and the V H of the antibody comprises:
(i) a V H CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22);
(ii) a V H CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and
(iii) a V H CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24); and
the C H of the antibody has a deletion corresponding to the C-terminal lysine residue at the last position of SEQ ID NO: 17, and further comprising informational material.

46 : The kit of claim 45 , wherein the informational material is selected from the group consisting of: information about production of the compound, molecular weight of the compound, concentration, date of expiration, and batch or production site information.

47 : The kit of claim 45 , wherein the informational material comprises instructions to administer the FcRn-binding antibody in a suitable manner.

48 : The kit of claim 45 , wherein the FcRn-binding antibody is a part of a composition.

49 : The kit of claim 48 , wherein the composition further comprises an ingredient selected from the group consisting of: a solvent or buffer, a stabilizer, a preservative, a flavoring agent, a fragrance or other cosmetic ingredient, and a second agent for treating an autoimmune disorder.

50 : The kit of claim 45 , further comprising one or more containers for the composition containing the FcRn antibody.

51 : A method of removing an unwanted therapeutic antibody from the bloodstream, comprising administering an FcRn-binding antibody to a subject, wherein the antibody comprises a light chain variable region (V L ), a heavy chain variable region (V H ), and a heavy chain constant region (C H ),
wherein the V L of the antibody comprises:
(i) a V L CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14);
(ii) a V L CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15); and
(iii) a V L CDR3 comprising the amino acid sequence CSYAGSGIYV (SEQ ID NO: 25), SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID NO: 13);
and the V H of the antibody comprises:
(i) a V H CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO:22);
(ii) a V H CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and
(iii) a V H CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24); and
the C H of the antibody has a deletion corresponding to the C-terminal lysine residue at the last position of SEQ ID NO: 17.

52 : A method of suppressing a level of anti-Human Leukocyte Antigens (HLA), comprising administering an FcRn-binding antibody to a subject, wherein the antibody comprises a light chain variable region (V L ), a heavy chain variable region (V H ), and a heavy chain constant region (C H ),
wherein the V L of the antibody comprises:
(i) a V L CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14);
(ii) a V L CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15); and
(iii) a V L CDR3 comprising the amino acid sequence CSYAGSGIYV (SEQ ID NO: 25), SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID NO: 13);
and the V H of the antibody comprises:
(i) a V H CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22);
(ii) a V H CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and
(iii) a V H CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24); and
the C H of the antibody has a deletion corresponding to the C-terminal lysine residue at the last position of SEQ ID NO: 17.

53 : The method of claim 52 , wherein the antibody is administered in connection with organ transplant.

54 : A method for delivering macro and/or micromolecules into a cell, comprising contacting an FcRn-binding antibody to the cell, wherein the antibody comprises a light chain variable region (V L ), a heavy chain variable region (V H ), and a heavy chain constant region (C H ),
wherein the V L of the antibody comprises:
(i) a V L CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14);
(ii) a V L CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15); and
(iii) a V L CDR3 comprising the amino acid sequence CSYAGSGIYV (SEQ ID NO: 25), SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID NO: 13);
and the V H of the antibody comprises:
(i) a V H CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22);
(ii) a V H CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23); and
(iii) a V H CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24); and
the C H of the antibody has a deletion corresponding to the C-terminal lysine residue at the last position of SEQ ID NO: 17.

55 : The method of claim 54 , wherein the antibody is administered in connection with gene therapy.

Assignees

• Dyax Corp

Inventors

• Sexton Daniel J
• Tenhoor Christopher
• Viswanathan Malini

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title